Details for Patent: 7,820,643
✉ Email this page to a colleague
Title: | Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
Abstract: | The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed. |
Inventor(s): | Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (San Diego, CA) |
Assignee: | Cypress Bioscience, Inc. (San Diego, CA) |
Filing Date: | Jul 18, 2003 |
Application Number: | 10/623,431 |
Claims: | 1. A method of treating fibromyalgia, the method consisting essentially of administering to a patient in need thereof i) an effective amount of at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof; and ii) an effective amount of at least one additional compound selected from pregabalin, a pharmaceutically acceptable salt of pregabalin, or a combination thereof; with the proviso that the method excludes administering phenylalanine, tyrosine, or tryptophan. 2. The method of claim 1, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are in the same dosage form. 3. The method of claim 1, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are in separate dosage forms. 4. The method of claim 3, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are administered simultaneously. 5. The method of claim 3, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are administered separately. 6. The method of claim 2, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are in the same oral dosage form. 7. The method of claim 3, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are in separate oral dosage forms. 8. The method of claim 1, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof is in tablet form. |